Intravitreal Bevacizumab for Diabetic Papillopathy
Authors:
- 24 March 2010
- journal article
- research article
- Published by SAGE Publications in Journal of Ocular Pharmacology and Therapeutics
- Vol. 26 (2) , 217-218
Abstract
A 43-year-old woman presented with a visual acuity of 1/10 in the right eye and 3/10 in the left eye. Ophthalmologic examination disclosed optic disc swelling on both sides with mild nonproliferative diabetic retinopathy. The pupils were equal and reactive without an afferent pupillary defect. Visual field testing showed no significant defect in both eyes. Systemic investigations revealed no abnormality. The patient was injected with bevacizumab intravitreally with the diagnosis of diabetic papillopathy (DP). Three weeks later, the vision increased to 7/10 in the right eye and optic disc edema disappeared. Intravitreal injection of bevacizumab effectively treated DP.Keywords
This publication has 7 references indexed in Scilit:
- Intravitreal Bevacizumab Treatment of Macular Edema Due to Optic Disc VasculitisOcular Immunology and Inflammation, 2009
- Combined Intravitreal Bevacizumab and Triamcinolone Acetonide Injection for Idiopathic NeuroretinitisOcular Immunology and Inflammation, 2009
- Treatment of Nonarteritic Anterior Ischemic Optic Neuropathy With Intravitreal BevacizumabJournal of Neuro-Ophthalmology, 2007
- Anti-VEGF Bevacizumab (Avastin®) for Radiation Optic NeuropathyAmerican Journal of Ophthalmology, 2007
- Intravitreal triamcinolone acetonide for the management of diabetic papillopathyAmerican Journal of Ophthalmology, 2004
- Periocular corticosteroids in diabetic papillopathyEye, 2004
- DIABETIC PAPILLOPATHY IN TYPE II DIABETIC PATIENTSRetina, 2002